

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

NCI-H929

RRID:CVCL_1600

Type: Cell Line

Proper Citation

RRID:CVCL_1600

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1600

Proper Citation: RRID:CVCL_1600

Description: Cell line NCI-H929 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: [PMID:2423157](#), [PMID:3275865](#), [PMID:8806089](#), [PMID:8806092](#), [PMID:8943038](#), [PMID:10087940](#), [PMID:10936422](#), [PMID:11157491](#), [PMID:12068308](#), [PMID:16956823](#), [PMID:17171682](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:18700954](#), [PMID:19306352](#), [PMID:21173094](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30285677](#), [PMID:30545397](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32123307](#), [PMID:35839778](#)

Comments: Characteristics: Produces IgA kappa., Population: Caucasian., Part of: RAS genetic alteration cell panel (ATCC TCP-1031)., Part of: MYC genetic alteration cell panel (ATCC TCP-1035)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H929

Synonyms: NCI H929, NCIH929, H929, H-929

Cross References: BTO:BTO_0002416, CLO:CLO_0008127, EFO:EFO_0001221, CLDB:cl3661, CLDB:cl3662, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770,

ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-1088, ATCC:CRL-3580, ATCC:CRL-9068, BCRC:60386, BioSample:SAMN03473361, BioSample:SAMN10988115, cancercellines:CVCL_1600, CCRID:1101HUM-PUMC000360, CCRID:4201HUM-CCTCC00300, CCTCC:GDC0300, Cell_Model_Passport:SIDM01148, ChEMBL-Cells:ChEMBL4295412, ChEMBL-Targets:ChEMBL4296391, CLS:305236, Cosmic:720769, Cosmic:724825, Cosmic:759905, Cosmic:760391, Cosmic:760392, Cosmic:886085, Cosmic:888022, Cosmic:1070716, Cosmic:1424217, Cosmic:2081399, Cosmic:2302415, Cosmic:2367293, Cosmic:2391791, Cosmic:2809759, Cosmic-CLP:724825, DepMap:ACH-000050, DSMZ:ACC-163, DSMZCellDive:ACC-163, ECACC:95050415, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS197CBA, ENCODE:ENCBS571AQH, GDSC:724825, GEO:GSM143333, GEO:GSM290290, GEO:GSM562817, GEO:GSM887452, GEO:GSM888532, GEO:GSM1374767, GEO:GSM1670271, IARC_TP53:28520, LiGeA:CCLE_061, Lonza:47, PharmacDB:NCIH929_1149_2019, PRIDE:PXD030304, Progenetix:CVCL_1600, PubChem_Cell_line:CVCL_1600, Wikidata:Q54908142

ID: CVCL_1600

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260829T234735+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H929.

No alerts have been found for NCI-H929.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 474 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Jiang K, et al. (2026) The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma. Molecular cancer therapeutics, 25(6), 1016.

Ng HL, et al. (2026) BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(25), e17231.

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. Cell reports. Medicine, 7(3), 102628.

Fang C, et al. (2026) Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. Cancer research, 86(8), 1956.

- Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. *Cell reports*, 45(6), 117464.
- Ghaemi B, et al. (2026) Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma. *Theranostics*, 16(6), 2748.
- Lin P, et al. (2026) CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models. *Blood cancer discovery*, 7(2), 234.
- Wang L, et al. (2025) Targeting of the CD161 Inhibitory Receptor Enhances Bone-Marrow-Resident Memory CD8+ T-Cell-Mediated Immunity against Multiple Myeloma. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(42), e10888.
- Yin Z, et al. (2025) Cinobufagin overcomes bortezomib resistance in multiple myeloma strains by targeting SEC62/TRPM4-mediated NECSO. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 147, 157171.
- Lowe E, et al. (2025) Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity. *The Journal of pharmacology and experimental therapeutics*, 392(8), 103634.
- Hussain T, et al. (2025) Therapeutic potential of PRMT1 as a critical survival dependency target in multiple myeloma. *BMC cancer*, 25(1), 1704.
- Tran S, et al. (2025) Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma. *Blood neoplasia*, 2(1), 100050.
- Wu D, et al. (2025) Optimization of a novel 2+2 BCMA x CD3 bispecific antibody for minimized cytokine release and potent efficacy. *Molecular cancer therapeutics*.
- Xu J, et al. (2025) IGF2BP1 promotes multiple myeloma with chromosome 1q gain via increasing CDC5L expression in an m6A-dependent manner. *Genes & diseases*, 12(1), 101214.
- Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. *Frontiers in immunology*, 16, 1518787.
- Nardone C, et al. (2025) Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma. *Molecular cell*, 85(13), 2597.
- Oikonomidi I, et al. (2025) Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cells. *PLoS biology*, 23(4), e3003096.
- Yao R, et al. (2025) Identification of a new micropeptide altKLF4 derived from KLF4 that influences myeloma chemotherapeutic sensitivity. *Cellular signalling*, 131, 111767.
- Simon S, et al. (2025) Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy. *Nature cancer*, 6(4), 647.
- Domagala J, et al. (2025) Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin. *Cancer research*, 85(13), 2448.